The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial was successfully launched outside of the US in May this year, with four Investigator Meetings conducted in May and June in order to initiate sites.
The first of those investigator meetings took place in Sydney, Australia on 4th May and was closely followed by a meeting in Hong Kong on 6th May for sites in Asia-Pacific.
For sites in the EU, the investigator meetings were split into two due to the large number of sites. Approximately half of the EU sites went to the meeting in Florence on the 20th of May 2011, followed by a second meeting in London on the 9th of June for the remaining sites.
Each of these meetings covered academic issues as well as the operational management of EXSCEL. Throughout the meetings, many of the practical aspects of the trial were explained in detail, from safety to clinical event reporting, and frequent question and answer sessions allowed participants to have their queries dealt with as soon as they arose.